RikOssenkoppele
@RikOssenkoppele
Followers
4K
Following
3K
Media
600
Statuses
1K
Neuroscientist | Alzheimer's disease | Dementia | PET, MRI, Fluid biomarkers | Cognition | Associate Professor @AlzheimerAms & @lunduniversity
Amsterdam, The Netherlands
Joined June 2010
The Alzheimer's disease 2024 drug development pipeline An often heard critique is that the Alzheimer field is too “amyloid-centric”. The Figure below actually shows a well-diversified drug pipeline, which is highly needed. The mechanisms of action (CADRO) for agents currently
4
60
196
So excited and honored to be invited to present the opening plenary at #AIC2025 this year in Toronto! 🧠 🙏 I would be very grateful if you could help me gather the most inspiring papers (including your own!) of the past year by completing this survey:
🚨Calling all neuroimagers! Help @EmmaCoomans shape the opening plenary at #AIC2025 (Toronto, July 26th) "Accomplishments of the Past Year" and share the most impactful neuroimaging research from the past year via this brief survey (~5min) by May 30th. https://t.co/5KpVMpzC7a
1
12
32
🚨NEW PREPRINT: An atypical phenotype is a risk factor for higher mortality in Alzheimer’s disease @ilse_bader shows that an atypical (non-amnestic-predominant) clinical presentation is an important risk factor for mortality beyond age, sex, education, APOEε4-carriership and
0
13
35
Survey among experts on the future role of tau-PET in clinical practice and trials Check out our latest work led by @vermeiren_marie & @IsmaelLCalandri, describing the results of a survey among 268 dementia experts on the future role of Tau PET in the clinic and trials. Many
0
8
40
IWG 2024 vs AA 2024 criteria for Alzheimer disease A comparison between the recently proposed Alzheimer Association criteria vs the updated IWG criteria for AD. Differences are in the Table below: mainly comprising differing views on AD as a "biological" vs "clinical-biological"
0
18
64
📢Job alert! Join the BioFINDER team as a Grant Manager👇🏽
🔎Job opportunity We are looking for a Grant Manager to make a significant contribution at all levels of the project lifecycle including identification of suitable funding calls, project application, project management and reporting Info: https://t.co/fcRM7VHp2K Spread the word!
0
0
1
Pleased to present the design paper of a Dutch multicenter study in which we aim to assess the clinical value of Tau PET, led by @vermeiren_marie (@AlzheimerAms). "The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP- TAU study" Link to
0
6
25
Pleased to present our recent publication @AlzheimersRes on "Biological mechanisms of resilience to tau pathology in Alzheimer’s disease", led by Anna Svenningson and Diana Bocancea. Link to paper: https://t.co/4VchXUc3WH w/@EStomrud, @NiklasMattsson4, @SebastianPalmqv,
0
9
58
REAL AD - Validation of a realistic screening approach for early Alzheimer's disease This large-scale study led by @_michael_scholl will learn us a lot about population-based screening with plasma biomarkers of Alzheimer's disease pathophysiology. Link to the design paper
1
2
37
On the train back to Amsterdam after a wonderful first @eumind_congress, I think is here to stay! It was a pleasure to give a talk on “AT(N) imaging in atypical variants of Alzheimer’s disease”.
1
5
28
Association of in vivo retention of Flortaucipir PET with tau neuropathology in corresponding brain regions Check out our most recent publication, led by @to_freiburghaus & @DW_Pawlik at Acta Neuropathologica. Main findings: 1⃣ Flortaucipir PET signal primarily reflects tau
1
8
30
isFTD2024 in Amsterdam has started! A great musical intro, official opening by local organizer Yolande Pijnenburg (@AlzheimerAms), a touching speech by Emma Heming Willis (FTD advocate and partner of Bruce Willis) and an opening plenary by Elisabet Englund (@lunduniversity)
0
2
23
I attended the FTD-ALS workshop (isFTD pre-conference in Amsterdam) this morning, learned a lot about TDP-43!
0
1
16
Lewy body pathology exacerbates brain hypo-metabolism and cognitive decline in Alzheimer’s disease Great work led by @LECollij. Using ADNI data, she showed that the presence of LB pathology (CSF SAA) exacerbates global cognitive decline in symptomatic AD and is associated with
2
30
117
Very proud of Anna Svenningson who defended her PhD thesis today very well. Also many thanks to opponent Prof. Geir Saelback for creating a great atmosphere leading to a high-level scientific discussion about resilience in Alzheimer’s disease. W/@OskarHansson9 @SebastianPalmqv
1
1
35
Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies Very elegant work from @biofinder_study, led by @alexa_pichetb, @_JakeVogel_ & @OskarHansson9. Link at @NatureNeuro > https://t.co/Kbo2Zsd0U0
0
14
78
The BeyeOMARKER study design paper is out! In BeyeOMARKER we will screen 700 individuals with plasma p-tau217 at an eye clinic, and further characterize 150 of them with Amyloid & Tau PET, MRI, retinal imaging and cognitive & cortical vision assessment. Thanks to the great team
3
10
51
Time for an update! @IsmaelLCalandri @Gill_Livingston @reparadela @LuCrivelliOk @NeuroAllegri @clausuemoto
🚨 NEW: @IsmaelLCalandri shows that Argentina has a higher population-attributable fraction (PAF) for dementia + different risk factor weights vs worldwide estimates. PDF: https://t.co/kfzlPKsyip w/@Gill_Livingston @reparadela @luCrivelliOk @NeuroAllegri @clausuemoto
1
2
21
The figure we all have to learn by heart: The updated Lancet Commission on potentially modifiable risk factors for dementia. #AAIC24
1
56
196